Clinical review for general practice

Gout is a systemic disease caused by the deposition of monosodium urate crystals in various tissues and organs with the subsequent development of autoinflammation. The problem of comorbidity in gout has been known for a long time and continues to be actively studied. The gout is associated with cardiovascular diseases, metabolic and metabolic disorders, kidney diseases, and hyperuricemia plays an important role in these associations. Therefore, the elimination of hyperuricemia is the basis of the modern strategy of effective therapy for gout, the main principle of which is “treat-to-target” (serum uric acide concentration <360 μmol/L [6 mg/dL]). Nevertheless, many patients who need treatment for gout still do not receive therapy or receive suboptimal therapy, which significantly increases the risks of overall and cardiovascular mortality. In this regard, it is of great importance that physicians are aware of the indications, optimal timing of initiation and purposes of urate-lowering therapy, as well as strengths and weaknesses of certain urate-lowering drugs, including skin, kidneys, heart, and liver adverse events. The review highlights the modern principles of urate-lowering therapy, including the place of febuxostat in the treatment of patients with gout.
Key words: gout, hyperuricemia, metabolic syndrome, urate-lowering therapy, allopurinol, febuxostat

1. Richette P, Bardin T. Gout. Lancet 2010; 375 (9711): 318–28. DOI: 10.1016/S0140-6736 (09)60883-7
2. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006; 8 Suppl 1 (Suppl. 1): S1. DOI: 10.1186/ar1906
3. Dalbeth N, Choi HK, Joosten LAB et al. Gout. Nat Rev Dis Primers. 2019; 5 (1): 69. Published 2019. DOI: 10.1038/s41572-019-0115-y
4. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10 (2): 417–26. DOI: 10.1016/s1097-2765 (02)00599-3
5. Martinon F, Pétrilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440 (7081): 237–41. DOI: 10.1038/nature04516
6. Рамеев В.В., Елисеев М.С., Моисеев С.В. Концепция аутовоспаления в генезе подагры и гиперурикемии. Клиническая фармакология и терапия. 2019; 28 (2): 28–33. DOI: 10.32756/0869-5490-2019-2-28-33
[Rameev V.V., Eliseev M.S., Moiseev S.V. Kontseptsiia autovospaleniia v geneze podagry i giperurikemii. Klinicheskaia farmakologiia i terapiia. 2019; 28 (2): 28–33. DOI: 10.32756/0869-5490-2019-2-28-33 (in Russian).]
7. Елисеев М.С. Подагра. В кн.: Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2020. ISBN: 978-5-9704-5398-8.
[Eliseev M.S. Podagra. In: Rossiiskie klinicheskie rekomendatsii. Revmatologiia. Ed, E.L. Nasonova. Moscow: GEOTAR-Media, 2020. ISBN: 978-5-9704-5398-8 (in Russian).]
8. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine 2011; 78 (1): 35–40. DOI: 10.1016/j.jbspin. 2010.02.027
9. Enomoto A, Kimura H, Chairoungdua A et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417 (6887): 447–52. DOI: 10.1038/nature742
10. Ichida K, Matsuo H, Takada T et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012; 3: 764. DOI: 10.1038/ncomms1756
11. Xu X, Li C, Zhou P, Jiang T. Uric acid transporters hiding in the intestine. Pharm Biol 2016; 54 (12): 3151–5. DOI: 10.1080/13880209. 2016.1195847
12. Jing J, Ekici AB, Sitter T et al. Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease. Sci Rep 2018; 8 (1): 13184. DOI: 10.1038/s41598-018-31282-z
13. Kuo CF, Grainge MJ, Mallen C et al. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 2016; 75 (1): 210–7. DOI: 10.1136/annrheumdis-2014-206410
14. Singh JA, Cleveland JD. Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data. RMD Open 2018; 4 (2): e000712. DOI: 10.1136/rmdopen-2018-000712
15. Kuo YJ, Tsai TH, Chang HP et al. The risk of atrial fibrillation in patients with gout: a nationwide population-based study. Sci Rep 2016; 6: 32220. DOI: 10.1038/srep32220
16. Clarson LE, Chandratre P, Hider SL et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2015; 22 (3): 335–43. DOI: 10.1177/204748 7313514895
17. Lottmann K, Chen X, Schädlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep 2012; 14 (2): 195–203. DOI: 10.1007/s11926-011-0234-2
18. Clarson LE, Hider SL, Belcher J et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis 2015; 74 (4): 642–7. DOI: 10.1136/annrheumdis-2014-205252
19. Abdul Sultan A, Mallen C, Hayward R et al. Gout and subsequent erectile dysfunction: a population-based cohort study from England. Arthritis Res Ther 2017; 19 (1): 123. DOI: 10.1186/s13075-017-
1322-0
20. Zhang Y, Peloquin CE, Dubreuil M et al. Sleep Apnea and the Risk of Incident Gout: A Population-Based, Body Mass Index-Matched Cohort Study. Arthritis Rheumatol 2015; 67 (12): 3298–302. DOI: 10.1002/art.39330
21. Blagojevic-Bucknall M, Mallen C, Muller S et al. The Risk of Gout Among Patients With Sleep Apnea: A Matched Cohort Study. Arthritis Rheumatol 2019; 71 (1): 154–60. DOI: 10.1002/art.40662
22. Huang CC, Huang PH, Chen JH et al. An Independent Risk of Gout on the Development of Deep Vein Thrombosis and Pulmonary Embolism: A Nationwide, Population-Based Cohort Study. Medicine (Baltimore) 2015; 94 (51): e2140. DOI: 10.1097/MD.0000000000002140
23. Li L, McCormick N, Sayre EC et al. Trends of venous thromboembolism risk before and after diagnosis of gout: a general population-based study. Rheumatology (Oxford) 2020; 59 (5): 1099–7. DOI: 10.1093/rheumatology/kez398
24. Kok VC, Horng JT, Wang MN et al. Gout as a risk factor for osteoporosis: epidemiologic evidence from a population-based longitudinal study involving 108,060 individuals. Osteoporos Int 2018; 29 (4): 973–85. DOI: 10.1007/s00198-018-4375-2
25. Tzeng HE, Lin CC, Wang IK et al. Gout increases risk of fracture: A nationwide population-based cohort study. Medicine (Baltimore) 2016; 95 (34): e4669. DOI: 10.1097/MD.0000000000004669
26. Roughley M, Sultan AA, Clarson L et al. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Arthritis Res Ther 2018; 20 (1): 243. DOI: 10.1186/s13075-018-1746-1
27. Singh JA, Cleveland JD. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. BMC Nephrol 2019; 20 (1): 93. DOI: 10.1186/s12882-019-1274-5
28. Shimizu T, Hori H. The prevalence of nephrolithiasis in patients with primary gout: a cross-sectional study using helical computed tomography. J Rheumatol 2009; 36 (9): 1958–62. DOI: 10.3899/jrheum.081128
29. Nakagawa T, Cirillo P, Sato W et al. The conundrum of hyperuricemia, metabolic syndrome, and renal disease. Intern Emerg Med 2008; 3 (4): 313–18. DOI: 10.1007/s11739-008-0141-3
30. King C, Lanaspa MA, Jensen T et al. Uric Acid as a Cause of the Metabolic Syndrome. Contrib Nephrol 2018; 192: 88–02. DOI: 10.1159/000484283А
31. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998; 148 (10): 958–966. DOI: 10.1093/oxfordjournals.aje.a009572
32. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28 (7): 1769–78. DOI: 10.2337/diacare.28.7.1769
33. Rho YH, Choi SJ, Lee YH et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005;
20 (6): 1029–33. DOI: 10.3346/jkms.2005.20.6.1029
34. Vázquez-Mellado J, García CG, Vázquez SG et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004; 10 (3): 105–9. DOI: 10.1097/01.rhu.0000129082.42094.fc
35. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120 (5): 442–7. DOI: 10.1016/j.amjmed.2006.06.040
36. Барскова В.Г. Метаболический синдром и кардиоваскулярные нарушения при подагре. Международный эндокринологический журнал. 2007; 6 (12). www.mif-ua.com/archive/article/3768
[Barskova V.G. Metabolicheskii sindrom i kardiovaskuliarnye narusheniia pri podagre. Mezhdunarodnyi endokrinologicheskii zhurnal. 2007; 6 (12). www.mif-ua.com/archive/article/3768 (in Russian).]
37. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76 (1): 29–42. DOI: 10.1136/annrheumdis-2016-
209707
38. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020; 16 (7): 380–90. DOI: 10.1038/s41584-020-0441-1
39. Doherty M, Jansen TL, Nuki G et al. Gout: why is this curable disease so seldom cured?. Ann Rheum Dis 2012; 71 (11): 1765–70. DOI: 10.1136/annrheumdis-2012-201687
40, Dehlin M, Ekström EH, Petzold M et al. Factors associated with initiation and persistence of urate-lowering therapy. Arthritis Res Ther 2017; 19 (1): 6. DOI: 10.1186/s13075-016-1211-y
41. FitzGerald JD, Dalbeth N, Mikuls T et al. 2020 American College of Rheumatology Guideline for the Management of Gout [published correction appears in Arthritis Care Res (Hoboken). 2020 Aug; 72 (8): 1187] [published correction appears in Arthritis Care Res (Hoboken). 2021 Mar; 73 (3): 458]. Arthritis Care Res (Hoboken) 2020; 72 (6): 744–60. DOI: 10.1002/acr.24180
42. Stamp LK, Chapman PT, Barclay ML et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 2017; 76 (9): 1522–8. DOI: 10.1136/annrheumdis-2016-210872
43. Stamp LK, Merriman TR, Barclay ML et al. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout. Semin Arthritis Rheum 2014; 44 (2): 170–4. DOI: 10.1016/j.semarthrit.2014.05.007
44. Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 2005; 331 (7517): 623–4. DOI: 10.1136/bmj.331.7517.623
45. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol [published correction appears in Proc Natl Acad Sci USA. 2005; 102 (17): 6237]. Proc Natl Acad Sci USA 2005; 102 (11): 4134–9. DOI: 10.1073/pnas.0409500102
46. Stamp LK, Taylor WJ, Jones PB et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64 (8): 2529–36. DOI: 10.1002/art.34488
47. Schumacher HR Jr, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009; 48 (2): 188–94. DOI: 10.1093/rheumatology/ken457
48. Schumacher HR Jr, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59 (11): 1540–8. DOI: 10.1002/art.24209
49. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353 (23): 2450–61. DOI: 10.1056/NEJMoa050373
50. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12 (2): R63. DOI: 10.1186/ar2978
51. Becker MA, Schumacher HR, MacDonald PA et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36 (6): 1273–82. DOI: 10.3899/jrheum.080814
52. Huang X, Du H, Gu J et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis 2014; 17 (6): 679–86. DOI: 10.1111/1756-185X.
12266
53. Mackenzie IS, Ford I, Nuki G et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020; 396 (10264): 1745 DOI: 57. DOI: 10.1016/S0140-6736 (20)32234-0
54. Fan B, Zhang P, Li X. Efficacy and safety of Febuxostat Versus Allopurinol in Hyperuricemic patients with or without Gout: A meta-analysis. Neuro Endocrinol Lett 2020; 41 (4): 195–204.
55. Fan M, Liu J, Zhao B et al. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clin Rheumatol 2021; 40 (2): 683–92. DOI: 10.1007/s10067-020-05272-4
56. Mizuno T, Hayashi T, Hikosaka S et al. Efficacy and safety of febuxostat in elderly female patients. Clin Interv Aging 2014; 9: 1489–93. DOI: 10.2147/CIA.S70855
57. Hira D, Chisaki Y, Noda S et al. Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment. Pharmacology 2015; 96 (1–2): 90–8. DOI: 10.1159/ 000434633
58. Lim DH, Oh JS, Ahn SM et al. Febuxostat in Hyperuricemic Patients With Advanced CKD [published correction appears in Am J Kidney Dis. 2017; 69 (6): 869]. Am J Kidney Dis 2016; 68 (5): 819–21. DOI: 10.1053/j.ajkd.2016.07.001
59. Juge PA, Truchetet ME, Pillebout E et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine 2017; 84 (5): 595–8. DOI: 10.1016/j.jbspin.2016.09.020
60. Liu X, Liu K, Sun Q et al. Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis. Exp Ther Med 2018; 16 (3): 1859–65. DOI: 10.3892/etm.2018.6367
61. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 2014; 37 (10): 919–25. DOI: 10.1038/ hr.2014.107
62. Zeng XX, Tang Y, Hu K et al. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine (Baltimore) 2018; 97 (13): e0161. DOI: 10.1097/MD. 0000000000010161
63. Bardin T, Chalès G, Pascart T et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 2016; 83 (3): 314–7. DOI: 10.1016/j.jbspin.2015.07.011
64. Чикина М.Н., Желябина О.В., Елисеев М.С. Влияние уратснижающей терапии на показатели качества жизни у пациентов с подагрой. Современная ревматология. 2021; 15 (3): 62–8.
[Chikina M.N., Zheliabina O.V., Eliseev M.S. Vliianie uratsnizhaiushchei terapii na pokazateli kachestva zhizni u patsientov s podagroi. Sovremennaia revmatologiia. 2021; 15 (3): 62–8 (in Russian).]

Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-10-2021/mnogolikaya_podagra_sovremennye_kontseptsii_lecheniya/